Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma) is a Japanese pharmaceutical company headquartered in Osaka, Japan, with a focus on psychiatry, neurology, oncology, and regenerative medicine. The company was formed through the merger of Sumitomo Pharmaceuticals (1913) and Dainippon Sumitomo Pharma (1897).
Sumitomo Pharma has evolved into a major Japanese pharmaceutical company with a strong focus on central nervous system disorders and innovative cell therapy programs. The company became Sumitomo Pharma in 2019 following brand unification[1].
The company traces its roots to two major pharmaceutical companies:
In 2005, Sumitomo Pharmaceuticals and Dainippon Sumitomo Pharma merged to form Sumitomo Dainippon Pharma, creating one of Japan's largest pharmaceutical companies.
The company rebranded to Sumitomo Pharma in 2019 to unify its global identity.
CTI-ND1601: iPSC-derived dopaminergic neuron progenitor cells for Parkinson's disease[2]
The cell therapy approach aims to replace lost dopamine-producing neurons in the substantia nigra, addressing the root cause of Parkinson's disease rather than just managing symptoms.
| Drug Candidate | Indication | Mechanism | Stage |
|---|---|---|---|
| SEP-363856 (Ultracelest) | Schizophrenia | TAAR1/5-HT1A agonist | Approved in Japan |
| DSP-5336 | Amyotrophic lateral sclerosis | RNA splicing modulator | Phase 1/2 |
| DSP-2230 | Neuropathic pain | Sodium channel blocker | Phase 1 |
| SEP-539190 | Parkinson's disease | Novel mechanism | Phase 1 |
Sumitomo's neuroscience pipeline addresses major neurodegenerative and psychiatric disorders[3]:
CTI-ND1601 represents one of the most advanced cell therapy approaches for Parkinson's disease:
SEP-363856 (Ultracelest) represents a new mechanism for schizophrenia[5]:
DSP-5336 targets RNA splicing in ALS:
DSP-2230 represents a novel approach to neuropathic pain:
Sumitomo's cell therapy platform leverages induced pluripotent stem cell (iPSC) technology:
Trace amine-associated receptor 1 (TAAR1) is a novel target for psychiatric disorders:
Revenue (FY2024): Approximately $3.5 billion USD (500 billion JPY)
R&D Investment: Approximately $800 million USD (120 billion JPY)
Key Focus Areas: CNS, oncology, regenerative medicine
Strategic Partnerships: Academic collaborations, biotech partnerships
Corporate History. Sumitomo Pharma History. ↩︎
CTI-ND1601 Program. ClinicalTrials.gov. ↩︎
Neuroscience Pipeline. R&D Presentation. ↩︎
iPSC Therapy for PD. Nature Reviews Drug Discovery. ↩︎
SEP-363856 Approval. PMDA Approval. ↩︎